Chronic urticaria: new management options

World Allergy Organization Journal

Paul A Greenberger¹ 

[1] Division of Allergy-Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, 676 N. St. Clair Street, # 14108, 60611 Chicago, IL, USA

关键词: Immunosuppressive;    Omalizumab;    H₁ receptor;    Antihistamine;    Vasculitis;    Chronic;    Urticaria;   

Others  :  1145476
DOI  :  10.1186/1939-4551-7-31

 received in 2014-04-17, accepted in 2014-09-30,  发布年份 2014

【 摘 要 】

Chronic urticaria is defined as episodic or daily hives lasting for at least 6 weeks and impairs quality of life. Two main subtypes include chronic idiopathic (spontaneous) urticaria and inducible (physical) urticaria, but some patients have urticarial vasculitis. “Autoimmune chronic urticaria” implies the presence of histamine releasing or mast cell activating autoantibodies to IgE or FcϵRI, the high affinity receptor on mast cells and basophils. In patients not readily controlled with labeled dosages of second generation H₁ receptor antagonists (antihistamines), there is evidence for reduction of urticaria using up to 4 fold increases in labeled dosages. The biologic modifier, omalizumab, helps to reduce lesions of chronic urticaria within 1–2 weeks.

【 授权许可】

   
2014 Greenberger; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Zuberbier T, Balke M, Worm M, Edenharter G, Mauer M: Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exper Dermatol 2010, 35:869-73.
• [2]Sanchez-Borges M, Asero R, Ansotegui IJ, Baiardini I, Bernstein JA, Canonica GW, Gower R, Kahn DA, Kaplan AP, Katelaris C, Maurer M, Park HS, Potter P, Saini S, Tassinari P, Tedeschi A, Ye YM, Zuberbier T, WAO Scientific and Clinical Issues Council: Diagnosis and treatment of urticaria and angioedema: a worldwide perspective. WAO J 2012, 5:125-47.
• [3]Gaig P, Olona M, Munoz Lejarazu D, Caballero MT, Dominguez FJ, Echechipia S, Garcia Abujeta JL, Gonzalo MA, Lleonart R, Martinez Cocera C, Rodriguez A, Ferrer M: Epidemiology of urticaria in Spain. J Invest Allergol Clin Immunol 2004, 14:214-20.
• [4]Kkakoo G, Sofianou-Katsoulis A, Perkin MR, Lack G: Clinical features and natural history of physical urticaria in children. Pediatr Allergy Immunol 2008, 19:363-6.
• [5]Ferrer M: Epidemiology, healthcare, resources, use and clinical features of different types of urticaria. Allergologica 2005. J Investig Allergol Clin Immunol 2009, 19(Suppl 2):21-6.
• [6]Elias J, Boss E, Kaplan AP: Studies of the cellular infiltrate of chronic idiopathic urticaria: prominence of T-lymphocytes, monocytes, and mast cells. J Allergy Clin Immunol 1986, 78:914-18.
• [7]Farkas Natbony S, Phillips ME, Elias JM, Godfrey HP, Kaplan AP: Histologic studies of chronic idiopathic urticaria. J Allergy Clin Immunol 1983, 71:177-83.
• [8]Haas N, Toppe E, Henz BM: Microscopic morphology of different types of urticaria. Arch Dermatol 1998, 134:41-46.
• [9]Sabroe RA, Poon E, Orchard GE, Lane D, Francis DM, Barr RM, Black MM, Black AK, Greaves MW: Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: a comparison of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies. J Allergy Clin Immunol 1999, 103:484-93.
• [10]Phanuphak P, Kohler PF, Stanford RE, Schocket AL, Carr RI, Claman HN: Vasculitis in chronic urticaria. J Allergy Clin Immunol 1980, 65:436-44.
• [11]Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, Church MK, Ensina LF, Gimenez-Arnau A, Godse K, Goncalo M, Grattan C, Hebert J, Hide M, Kaplan A, Kapp A, Abdul Latiff AH, Mathelier-Fusade P, Metz M, Nast A, Saini SS, Sanchez-Borges M, Schmid-Grendelmeier P, Simons FER, Staubach P, Sussman G, Toubi E, Vena GA, Wedi B, Zhu XJ, Maurer M: The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014, 69:868-87.
• [12]Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh F, Sheikh J, Weldon D, Zuraw B, Bernstein DI, Blessing-Moore J, Cox L, Nicklas RA, Oppenheimer J, Portnoy JM, Randolph CR, Schuller DE, Spector SL, Tilles SA, Wallace D: The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol 2014, 133:1270-7. 10.1016/j.jaci.2014.02.036
• [13]Van Der Valk PGM, Moret G, Kiemeney ALM: The natural history of chronic urticaria and angioedema in patients visiting a tertiary referral centre. Br J Dermatol 2002, 146:110-13.
• [14]Hiragun M, Hiragun T, Mihara S, Akita T, Tanaka J, Hide M: Prognosis of chronic spontaneous urticaria in 117 patients not controlled by a standard dose of antihistamine. Allergy 2013, 68:229-35.
• [15]Sahiner UM, Civelek E, Tuncer A, Tolga Yavuz S, Karablut E, Sackesen C, Sekerel BE: Chronic urticaria: Etiology and natural course in children. Int Arch Allergy Immunol 2011, 156:224-30.
• [16]Rabelo-Filardi R, Daltro-Oliveira R, Campos RA: Parameters associated with chronic spontaneous urticaria duration and severity: a systematic review. Int Arch Allergy Immunol 2013, 161:197-204.
• [17]Nebiolo F, Bergia R, Bommarito L, Bugiani M, Heffler E, Carosso A, Castiglioni G, Guida G, Badiu I, Pizzimenti S, Mietta S, Ferrero N, Rolla G: Effect of arterial hypertension on chronic urticaria duration. Ann Allergy Asthma Immunol 2009, 103:407-10.
• [18]Ye Y-M, Yang E-M, Yoo H-S, Shin Y-S, Kim S-H, Park H-S: Increased level of basophil CD203c expression predicts severe chronic urticaria. J Korean Med Sci 2014, 29:43-7.
• [19]Asero R: D-dimer: a biomarker for antihistamine-resistant chronic urticaria. J Allergy Clin Immunol 2013, 132:983-5.
• [20]Toubi E, Kessel A, Avshovich N, Bamberger E, Sabo E, Nusem D, Panasoff J: Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy 2004, 59:869-73.
• [21]Magen E, Mishal J, Zeldin Y, Schlesinger M: Clinical and laboratory features of antihistamine-resistant chronic idiopathic urticaria. Allergy Asthma Proc 2011, 32:460-6.
• [22]Maurer M, Rosen K, Hsieh H-J, Saini S, Grattan C, Gimenez-Arnau A, Agarwal S, Doyle R, Canvin J, Kaplan A, Casale T: Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013, 368:924-35.
• [23]Vestergaard C, Deleuran M: Two cases of severe refractory chronic idiopathic urticaria treated with omalizumab. Acta Derm-Venereol 2010., 90doi:10.2340/00015555-0884
• [24]Metz M, Ohanyan T, Church MK, Maurer M: Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. J Dermato Sci 2013, 73:57-62.
• [25]Saavedra M, Sur S: Down regulation of the high-affinity IgE receptor associated with successful treatment of chronic idiopathic urticaria with omalizumab. Clin Molec Allergy 2011, 9:2. BioMed Central Full Text
• [26]Saini S, Rosen KE, Hsieh H-J, Wong DA, Conner E, Kaplan A, Spector S, Maurer M: A randomized, placebo-controlled, dose ranging study of single-dose omalizumab in patients with H1-antihistamine refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011, 128:567-73.
• [27]Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E, Veith J, Kamath N, Stabach P, Jakob T, Stirling RG, Kuna P, Berger W, Maurer M, Rosen K: Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013, 132:101-9.
• [28]Sussman G, Hebert J, Barron C, Bian J, Caron-Guay RM, Laflamme S, Stern S: Real-life experiences with omalizumab for the treatment of chronic urticaria. Ann Allergy Asthma Immunol 2013, 112:170-4.
• [29]Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S: Omalizumab-induced reductions in mast cell FcϵRI expression and function. J Allergy Clin Immunol 2004, 114:527-30.
• [30]Kay AB, Ying S, Ardelean E, Mlynek A, Kita H, Clark P, Maurer M: Elevations in vascular markers and eosinophils in chronic spontaneous urticarial weals with low-level persistence in uninvolved skin. Br J Dermatol 2014, 171:505-11.
• [31]Piliponsky AM, Gleich GJ, Bar I, Levi-Schaffer F: Effects of eosinophils on mast cells: a new pathway for the perpetuation of allergic inflammation. Mol Immunol 2001, 38:1369-72.
• [32]Staevska M, Todor TA, Kralimarkova T, Lazarova C, Kraeva S, Popova D, Church DS, MD , Dimitrov V, Church MK: The effectiveness of levocetirizine and desloratadine in up to 4 times the conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol 2010, 125:676-82.
• [33]Greene SL, Reed CE, Schroeter AL: Double-blind crossover study comparing doxepin with diphenhydramine for the treatment of chronic urticaria. J Am Acad Dermatol 1985, 12:669-75.
• [34]Goldsobel AB, Rohr AS, Siegel SC, Spector SL, Katz RM, Rachelefsky GS, Drayton G, Indianer L, Peter JB, Barr RJ, et al.: Efficacy of doxepin in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1986, 78:867-73.
• [35]Bernstein JA, Greenberger PA, Patterson R, Glass M, Krell R, Thyrum PT: The effect of the oral leukotriene antagonist, ICI 204, 219, on leukotriene D4 and histamine-induced cutaneous vascular reactivity in man. J Allergy Clin Immunol 1991, 87:93-8.
• [36]Soter NA, Lewis RA, Corey EJ, Austen KF: Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin. J Invest Derm 1983, 80:115-9.
• [37]Bagenstose SE, Levin L, Bernstein JA: The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. J Allergy Clin Immunol 2004, 113:134-40.
• [38]Erbagci Z: The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: A single-blind, placebo-controlled, crossover clinical study. J Allergy Clin Immunol 2002, 110:484-8.
• [39]Kosnik M, Subic T: Add-on montelukast in antihistamine-resistant chronic idiopathic urticaria. Resp Med 2011, 105:S84-S88.
• [40]Di Lorenzo G, D’Alcamo A, Rizzo M, Leto-Barone MS, Lo Bianco C, Ditta V, Politi D, Castello F, Pepe I, Di Fede G, Rini GB: Leukotriene receptor antagonists in monotherapy or in combination with antihistamines in the treatment of chronic urticaria: a systematic review. J Asthma Allergy 2009, 2:9-16.
• [41]Boubouka C, Charissi C, Kouimintzis D, Kalogeromitros D, Stavro-Poulos P, Katsarou A: Treatment of autoimmune urticaria with low-dose cyclosporine A: a one-year follow-up. Acta Derm Venerol 2011, 91:50-4.
• [42]Kessel A, Toubi E: Cyclosporine-A in severe chronic urticaria: the option for long-term therapy. Allergy 2010, 65:1478-82.
• [43]Vena GA, Cassano N, Colombo D, Peruzzi E, Pigatto P: Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2006, 55:705-9.
• [44]Inaloz HS, Ozturk S, Akcali C, Kirtak N, Tarakcioglu M: Low-dose and short-term cyclosporine treatment in patients with chronic idiopathic urticaria: a clinical and immunological evaluation. J Dermatol 2008, 35:276-82.
• [45]Grattan CE, O’Donnell BF, Francis DM, Niimi N, Barlow RJ, Seed PT, Kobza Black A, Greaves M: Randomized double-blind study of cyclosporine in chronic “idiopathic” urticaria. Br J Dermatol 2000, 143:365-72.
• [46]Kessel A, Bamberger E, Toubi E: Tacrolimus in the treatment of severe chronic idiopathic urticaria: An open-label prospective study. J Am Acad Dermatol 2005, 52:145-8.
• [47]Shahar E, Bergman R, Guttman-Yassky E, Pollack S: Treatment of severe chronic idiopathic urticaria with oral mycophenolate mofetil in patients not responding to antihistamines and/or corticosteroids. Int J Dermatol 2006, 45:1224-7.
• [48]Zimmerman AB, Berger EM, Elmariah SB, Soter NA: The use of mycophenolate mofetil for the treatment of autoimmune and chronic idiopathic urticaria: experience in 19 patients. J Am Acad Dermatol 2011, 66:767-70.
• [49]Perez A, Woods A, Grattan CEH: Methotrexate: a useful steroid-sparing agent in recalcitrant chronic urticaria. Br J Dermatol 2010, 162:191-4.
• [50]Tedeschi A: Paradoxical exacerbation of chronic urticaria by H1-antihistamines and montelukast. Eur Ann Allergy Clin Immunol 2009, 41:187-9.
• [51]Hashimoto T, Kawakami T, Ishii N, Ishii K, Karashima T, Nakama T, Tsuruta D, Dainichi T, Hide M, Hamada T: Mizoribine treatment for antihistamine-resistant chronic autoimmune urticaria. Dermatol Ther 2012, 25:379-81.
• [52]Khan DA: Alternative agents in refractory chronic urticaria: Evidence and considerations on their selection and use. J Allergy Clin Immunol: In Practice 2013, 1:433-40.
• [53]Aseri R, Tedeschi A, Cugno M: Treatment of refractory chronic urticaria: current and future therapeutic options. Am J Clin Dermatol 2013, 14:461-8.
• [54]Kaplan AP: Treatment of chronic spontaneous urticaria. Allergy Asthma Immunol Res 2012, 4:326-331.
• [55]Joint Task Force on Practice Parameters: The diagnosis and management of urticaria: a practice parameter part I:acute urticaria/angioedema part II: chronic urticaria/angioedema. Ann Allergy Asthma Immunol 2000, 85:521-44.
• [56]Ortonne J-P: Chronic urticaria: a comparison of management guidelines. Expert Opinion Pharmacother 2011, 12:2683-93.
• [57]Georgy MS, Grammer LC, Greenberger PA, Peters AT: A retrospective chart review of the use of colchicine for the treatment of refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2010, 125:AB96.
• [58]Martinez BA, Hanson IC, Davis CM: Colchicine use in resistant urticaria and angioedema patients: a case series. J Allergy Clin Immunol 2007, 119:S200.
• [59]Pho LN, Eliason MJ, Regruto M, Hull CM, Powell DL: Treatment of chronic urticaria with colchicine. J Drugs Dermatol 2011, 10:1423-8.
• [60]Engin B, Ozdemir M: Prospective randomized non-blinded clinical trial on the use of dapsone plus antihistamine vs. antihistamine in patients with chronic idiopathic urticaria. J Eur Acad Dermatol Venereol 2008, 22:481-6.
• [61]Cooke AJ, Morgan M, Rogers L, Huet-Adams B, Khan DA: Double-blind placebo controlled (DBPC) trial of dapsone in antihistamine refractory chronic idiopathic urticaria (CIU). J Allergy Clin Immunol 2013, 131:AB143.
• [62]Cassano N, D’Argento V, Filotico R, Veno GA: Low-dose dapsone in chronic idiopathic urticaria: preliminary results of an open study. Acta Derm Venerol 2005, 85:254-5.
• [63]McGirt LY, Vasagar K, Gober LM, Saini SS, Beck LA: Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine. Arch Dermatol 2006, 142:1337-42.
• [64]Orden RA, Timble H, Saini SS: Efficacy and safety of sulfasalazine in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2014, 112:64-70.
• [65]Asero R, Tedeschi A, Cugno M: Heparin and tranexamic acid therapy may be effective in treatment-resistant chronic urticaria with elevated d-dimer: a pilot study. Int Arch Allergy Immunol 2010, 152:384-9.
• [66]Cugno M, Marzano AV, Tedeschi A, Fanoni D, Venegoni L, Asero R: Expression of tissue factor by eosinophils in patients with chronic urticaria. Int Arch Allergy Immunol 2009, 148:170-4.
• [67]Parslew R, Pryce D, Ashworth J, Friedmann PS: Warfarin treatment of chronic idiopathic urticaria and angio-oedema. Clin Exper Allergy 2000, 30:1161-5.
• [68]Magerl M, Rother M, Bieber T, Biedermann T, Brasch J, Dominicus R, Hunzelmann N, Jakob T, Mahler V, Popp G, Schäkel K, Schlingensiepen R, Schmitt J, Siebenhaar F, Simon JC, Staubach P, Wedi B, Weidner C, Maurer M: Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria. J Eur Acad Dermatol Venereol 2013, 27:e363-9.